This database contains 30 studies, archived under the term: "Neurology"
Click here to filter this large number of results.
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S.,
Walsh, S.,
Little, J. T.,
Behan, K.,
Reynolds, B.,
Ward, C.,
Jin, S.,
Thomas, R.,
Aisen, P. S.
Objective: Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD).; Methods: We assessed the safety, tolerability, and efficacy of huperzine A in mild to moderate AD in a multicenter trial in which 210 […]
Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study
Coker, L. H.,
Hogan, P. E.,
Bryan, N. R.,
Kuller, L. H.,
Margolis, K. L.,
Bettermann, K.,
Wallace, R. B.,
Lao, Z.,
Freeman, R.,
Stefanick, M. L.,
Shumaker, S. A.
Objective: The Women’s Health Initiative Memory Study (WHIMS) hormone therapy (HT) trials reported that conjugated equine estrogen (CEE) with or without medroxyprogesterone acetate (MPA) increases risk for all-cause dementia and global cognitive decline. WHIMS MRI measured subclinical cerebrovascular disease as a possible mechanism to explain cognitive decline reported in WHIMS.; Methods: We contacted 2,345 women […]
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H.,
Doody, R. S.,
Kivipelto, M.,
Sparks, D. L.,
Waters, D. D.,
Jones, R. W.,
Schwam, E.,
Schindler, R.,
Hey-Hadavi, J.,
DeMicco, D. A.,
Breazna, A.
Background: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD.; Methods: This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to […]
Validity of the free and cued selective reminding test in predicting dementia: the 3C study
Auriacombe, S.,
Helmer, C.,
Amieva, H.,
Berr, C.,
Dubois, B.,
Dartigues, J. F.
Objective: We assessed the validity of the Free and Cued Selective Reminding Test (FCSRT) in predicting dementia 2 and 5 years after initial evaluation in a population-based cohort over age 65 years participating in the French 3 Cities (3C) study.; Methods: The FCSRT was administered at baseline along with demographics, cognitive and functional scales, and […]
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Gilman, S.,
Fox, N. C.,
Blennow, K.,
Raskind, M.,
Sabbagh, M.,
Honig, L. S.,
Doody, R.,
van Dyck, C. H.,
Mulnard, R.,
Barakos, J.,
Gregg, K. M.,
Liu, E.,
Lieberburg, I.,
Schenk, D.,
Black, R.,
Grundman, M.
Background: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.; Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). […]
Donepezil delays progression to AD in MCI subjects with depressive symptoms
Lu, P. H.,
Edland, S. D.,
Teng, E.,
Tingus, K.,
Petersen, R. C.,
Cummings, J. L.
Objective: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship.; Methods: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer’s Disease Cooperative Study drug trial […]
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial
Doody, R. S.,
Ferris, S. H.,
Salloway, S.,
Sun, Y.,
Goldman, R.,
Watkins, W. E.,
Xu, Y.,
Murthy, A. K.
Background: Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.; Methods: In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks) or placebo treatment. Primary efficacy variables included change […]
Vitamins B(12), B(6), and folic acid for cognition in older men
Ford, A. H.,
Flicker, L.,
Alfonso, H.,
Thomas, J.,
Clarnette, R.,
Martins, R.,
Almeida, O. P.
Objective: To investigate whether supplementing older men with vitamins B(12), B(6), and folic acid improves cognitive function.; Methods: The investigators recruited 299 community-representative hypertensive men 75 years and older to a randomized, double-blind controlled clinical trial of folic acid, vitamin B(6), and B(12) supplementation vs placebo over 2 years. The primary outcome of interest was […]
Physical activity attenuates age-related biomarker alterations in preclinical AD
Okonkwo, O. C.,
Schultz, S. A.,
Oh, J. M.,
Larson, J.,
Edwards, D.,
Cook, D.,
Koscik, R.,
Gallagher, C. L.,
Dowling, N. M.,
Carlsson, C. M.,
Bendlin, B. B.,
LaRue, A.,
Rowley, H. A.,
Christian, B. T.,
Asthana, S.,
Hermann, B. P.,
Johnson, S. C.,
Sager, M. A.
Objective: To examine whether engagement in physical activity might favorably alter the agedependent evolution of Alzheimer disease (AD)-related brain and cognitive changes in a cohort of at-risk, late-middle-aged adults. Methods: Three hundred seventeen enrollees in the Wisconsin Registry for Alzheimer’s Prevention underwent T1 MRI; a subset also underwent ¹¹C-Pittsburgh compound B–PET (n = 186) and […]
One-year safety and tolerability profile of pridopidine in patients with Huntington disease
Squitieri, Ferdinando,
Landwehrmeyer, Bernhard,
Reilmann, Ralf,
Rosser, Anne,
de Yebenes, Justo Garcia,
Prang, Allan,
Ivkovic, Jelena,
Bright, Jeremy,
Rembratt, Åsa
Objective: To assess the 1-year safety profile of the dopaminergic stabilizer pridopidine in patients with Huntington disease. Methods: Patients received pridopidine 45 mg/day for 4 weeks then pridopidine 90 mg/day for 22 weeks in this 6-month open-label extension (OLE) of the 6-month MermaiHD randomized controlled trial (RCT). Any adverse events (AEs) were recorded. Patients were […]